186 related articles for article (PubMed ID: 26993418)
1. Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.
Rasmussen JH; Håkansson K; Vogelius IR; Aznar MC; Fischer BM; Friborg J; Loft A; Kristensen CA; Bentzen SM; Specht L
Radiother Oncol; 2016 Jul; 120(1):76-80. PubMed ID: 26993418
[TBL] [Abstract][Full Text] [Related]
2. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of
Berwouts D; Madani I; Duprez F; Olteanu AL; Vercauteren T; Boterberg T; Deron P; Bonte K; Huvenne W; De Neve W; Goethals I
Head Neck; 2017 Nov; 39(11):2264-2275. PubMed ID: 28833829
[TBL] [Abstract][Full Text] [Related]
4. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
5. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
de Leeuw ALMP; Giralt J; Tao Y; Benavente S; France Nguyen TV; Hoebers FJP; Hoeben A; Terhaard CHJ; Wai Lee L; Friesland S; Steenbakkers RJHM; Tans L; Heukelom J; Kayembe MT; van Kranen SR; Bartelink H; Rasch CRN; Sonke JJ; Hamming-Vrieze O
Radiother Oncol; 2024 Jul; 196():110281. PubMed ID: 38636708
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc.
Differding S; Sterpin E; Hermand N; Vanstraelen B; Nuyts S; de Patoul N; Denis JM; Lee JA; Grégoire V
Radiat Oncol; 2017 Mar; 12(1):59. PubMed ID: 28335778
[TBL] [Abstract][Full Text] [Related]
8. [Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up].
Hideghéty K; Cserháti A; Besenyi Z; Zag L; Gaál S; Együd Z; Mózes P; Szántó E; Csenki M; Rusz O; Varga Z; Dobi Á; Maráz A; Pávics L; Lengyel Z
Magy Onkol; 2015 Jun; 59(2):103-10. PubMed ID: 26035157
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy.
Adams G; Porceddu SV; Pryor DI; Panizza B; Foote M; Rowan A; Burmeister B
Head Neck; 2014 Aug; 36(8):1200-6. PubMed ID: 23893554
[TBL] [Abstract][Full Text] [Related]
10. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Yoon DH; Cho Y; Kim SY; Nam SY; Choi SH; Roh JL; Lee SW; Song SY; Lee JH; Kim JS; Cho KJ; Kim SB
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):118-25. PubMed ID: 20675065
[TBL] [Abstract][Full Text] [Related]
12. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
13. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.
van den Bosch S; Dijkema T; Kunze-Busch MC; Terhaard CH; Raaijmakers CP; Doornaert PA; Hoebers FJ; Vergeer MR; Kreike B; Wijers OB; Oyen WJ; Kaanders JH
BMC Cancer; 2017 Mar; 17(1):208. PubMed ID: 28327089
[TBL] [Abstract][Full Text] [Related]
14. Methodology for adaptive and robust FDG-PET escalated dose painting by numbers in head and neck tumors.
Differding S; Sterpin E; Janssens G; Hanin FX; Lee JA; Grégoire V
Acta Oncol; 2016; 55(2):217-25. PubMed ID: 26079436
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
16. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
17. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
[TBL] [Abstract][Full Text] [Related]
18. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
20. Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting.
Rasmussen JH; Vogelius IR; Aznar MC; Fischer BM; Christensen CB; Friborg J; Loft A; Kristensen CA; Bentzen SM; Specht L
Acta Oncol; 2015; 54(9):1416-22. PubMed ID: 26343280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
